Altered gene expression in drug-resistant human breast cancer cells

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2405-2414

  Wosikowski, Katja ^a   Schuurhuis, Danita ^a,c   Kops, Geert J P L ^a   Saceda, Miguel ^b,d   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GROWTH RATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR DENSITY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, ESTROGEN; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0031417680     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Morrow, C. S., and Cowan, K. H. Mechanisms of antineoplastic drug resistance. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles & Practice of Oncology, pp. 340-348. Philadelphia: J. B. Lippincott Co., 1993.
2. Lee, S. A., Karaszkiewicz, J. W., and Anderson, W. B. Elevated level of nuclear protein kinase C in multidrug resistant MCF-7 human breast carcinoma cells. Cancer Res., 52: 3750-3759, 1992.
3. Kacinski, B. M., Yee, L. D., Carter, D., Li, D., and Kuo, M. T. Human breast carcinoma cell levels of MDR-1 (P-glycoprotein) transcripts correlate in vivo inversely and reciprocally with tumor progesterone receptor content. Cancer Commun., 1: 1-6, 1989.
4. Meyers, M. B., Shen, W. P. V., Spengler, B. A., Ciccarone, V., O'Brien, J. P., Donner, D. B., Furth, M. E., and Biedler, J. L. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J. Cell. Biochem., 38: 87-97, 1988.
5. Sommers, C. L., Heckford, S. E., Skerker, J. M., Worland, P., Torri, J. A., Thompson, E. W., Byers, S. W., and Gelmann, E. P. Loss of epithelial markers and acquisition of vimentin expression in Adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res., 52: 5190-5197, 1992.
6. Takano, H., Kohono, K., Shiraishi, N., Sato, S., Asoh, K., Yakushinji, M., Ono, M., and Kuwano, M. Altered expression of epidermal growth factor receptor gene in a classical multidrug-resistant variant of a human cancer cell line KB. Jpn. J. Cancer Res., 80: 373-379, 1989.
7. Dickstein, B., Valverius, E. M., Wosikowski, K., Saceda, M., Pearson, J. W., Martin, M. B., and Bates, S. E. Increased epidermal growth factor receptor in an estrogen-responsive, Adriamycin-resistant MCF-7 cell line. J. Cell. Physiol., 157: 110-118, 1993.
8. Brown, R., Clugston, C., Burns, P., Edlin, A., Vasey, P., Vojtesek, B., and Kaye, S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55: 678-684, 1993.
9. Lee, W-P. The role of reduced growth rate in the development of drug resistance of HOB1 lymphoma cells to vincristine. Cancer Lett., 73: 105-111, 1993.
10. Dickstein, B., Wosikowski, K., and Bates, S. E. Resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol. Cell. Endocrinol., 110: 205-211, 1995.
11. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1992.
12. Isonishi, S., Hom, D. K., Thiebaut, F. B., Mann, S. C., Andrews, P. A., Basu, A., Lazo, J. S., Eastman, A., and Howell, S. B. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells reduces resistance to cisplatin. Cancer Res., 51: 5903-5909, 1991.
13. Miyashita, T., and Reed, J. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res., 52: 5407-5411, 1992.
14. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
15. Scanlon, K. J., Ishida, H., and Kaashani-Sabet, M. Ribozyme-mediated reversal of the multidrug resistant phenotype. Proc. Natl. Acad. Sci. USA, 91: 11123-11127, 1994.
16. Cornwell, M. M., and Smith, D. E. A signal transduction pathway for activation of the mdr1 promotor involves the proto-oncogene c-raf kinase. J. Biol. Chem., 265: 15347-15350, 1993.
17. Vickers, P. J., Dickson, R. B., Shoemaker, R., and Cowan, K. H. A multidrug resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol. Endocrinol., 2: 886-892, 1988.
18. Nicholson, S., Richard, J., Sainsbury, C., Halcrow, P., Kelly, P., Angus, B., Wright, C., Henry, J., Farson, J. R., and Harris, A. L. Epidermal growth factor receptor: results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br. J. Cancer, 63: 146-150, 1991.
19. Sainsbury, J. R. C., Farndon, J. R., Needham, G. K., Malcolm, A. J., and Harris, A. L. Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, i: 1398-1402, 1987.
20. Costa, S., Stamm, H., Almendral, A., Ludwig, H., Wyss, R., Fabbro, D., Ernst, A., Takahashi, A., and Eppenberger, U. Predictive value of EGF receptor in breast cancer. Lancet, ii: 1258, 1988.
21. Fox, S. B., Smith, K., Hollyer, J., Greenall, M., Hastrich, D., and Harris, A. L. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat., 29: 41-49, 1994,
22. Graves, J. D., Campbell, J. S., and Krebs, E. G. Protein serine/ threonine kinases of the MAPK cascade. Ann. NY Acad. Sci., 766: 320-343, 1995.
23. Normanno, N., Ciardiello, F., Brandt, R., and Salomon, D. S. Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Res. Treat., 29: 11-27, 1994.
24. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S. A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family and evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA, 86: 9193-9197, 1989.
25. King, C. R., Kraus, M. H., and Aaronson, S. A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (Washington DC), 229: 974-976, 1985.
26. erbB4, a fourth member of the epidermal growth factor family. Proc. Natl. Acad. Sci. USA, 90: 1746-1750, 1993.
27. Earp, H. S., Dawson, T. L., Li, X., and Yu, H. Heterodimerisation and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat., 35: 115-132, 1995.
28. Peles, E., and Yardeb, Y. Neu and its ligands: from an oncogene to neural factors. BioEssays, 15: 815-824, 1993.
29. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
30. Gasparini, G., Gullick, W. J., Bevilacqua, P., Sainsbury, J. R. C., Meli, S., Boracci, P., Testolin, A., LaMalfa, G., and Pozza, F. Human breast cancer: prognostic significance of the c-erbB2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathological features. J. Clin. Oncol., 10: 686-695, 1992.
31. McCann, A. H., Dervan, P. A., O'Regan, M., Codd, M. B., Gullick, W. J., Tobin, B. M. J., and Carney, D. N. Prognostic significance of c-erbB2 and estrogen receptor status in human breast cancer. Cancer Res., 51: 3296-3303, 1991.
32. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
33. Masiakowski, P., Breathnach, R., Bloch, J., Gannon, F., Krust, A., and Chambon, P. Cloning of cDNA sequences of hormone-regulated genes form the MCF-7 human breast cancer cell line. Nucleic Acids Res., 10: 7895-7903, 1982.
34. Bell, G. I., Fong, N. M., Stempien, M. M., Wormsted, M. A., Caput, D., Ku, L., Urdea, M. S., Rall, L. B., and Sanchez-Prescador, R. Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res., 14: 8427-8446, 1986.
35. Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., Chen, E., Jacobs, S., Trancke, U., Ramachandran, J., and Fujita-Yamaguchi, Y. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J., 5: 2503-2512, 1986.
36. Plowman, G., Green, J., McDonald, V., Neubauer, M. A., Disteche, C., Todaro, G., and Shoyab, M. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor inhibitory activity. Mol. Cell. Biol., 10: 1967-1981, 1990.
37. Plowman, G. D., Whitney, G. S., Neubauer, M. G., Green, J. M., McDonald, V. L., Todaro, G. J., and Shoyab, M. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc. Natl. Acad. Sci. USA, 87: 4905-4909, 1990.
38. Mickley, L., Bates, S., Richert, N., Currier, S., Tanaka, S., Foss, F., Rosen, N., and Fojo, A. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J. Biol. Chem., 264: 18031-18040, 1989.
39. Sambrook, J., Fritsch, E. F., and Maniatis, T. Extraction, purification, and analysis of messenger RNA from eukaryotic cells. In: C. Nolan, N. Ford, and M. Ferguson (eds.), Molecular Cloning: A Laboratory Manual, pp. 7.3-7.83. New York: Cold Spring Harbor Laboratory, 1989.
40. Herrin, D. L., and Schmidt, G. W. Rapid, reversible staining of Northern blots prior to hybridization. BioTechniques, 6: 196-200, 1988.
41. Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K., and Green, M. R. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res., 12: 7035-7056, 1984.
42. Saceda, M., Knabbe, C., Dickson, R. B., Lippman, M. E., Bronzert, D., Lindsey, R. K., Gottardis, M. M., and Martin, M. B. Post-transcriptional destabilization of estrogen receptor mRNA in MCF-7 cells by 12-O-tetradecanoylphorbol-13-acetate. J. Biol. Chem., 266: 17809-17814, 1991.
43. Sartor, O., Sameshima, J. H., and Robbins, K. C. Differential association of cellular proteins with family protein-tyrosine kinases. J. Biol. Chem., 266: 6462-6466, 1991.
44. Chen, Y-N., Mickley, L. A., Schwartz, A. M., Acton, E. M., Hwang, J., and Fojo, A. T. Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem., 265: 10073-10080, 1990.
45. Kreipe, H., Alm, P., Olsson, H., Hauberg, M., Fischer, L., and Parwaresch, R. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am. J. Pathol., 142: 651-657, 1993.
46. Boege, F., Andersen, A., Jensen, S., Zeidler, R., and Kreipe, H. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am. J. Pathol., 146: 1302-1308, 1995.
47. Camplejohn, R. S., Brock, A., Barnes, D. M., Gillett, C., Raikundalia, B., Kreipe, H., and Parwaresch, M. R. Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cells. Br. J. Cancer, 67: 657-662, 1993.
48. Hendler, F., and Ozanne, B. Human squamous cell lung cancers express increased epidermal growth factor receptors. J. Clin. Invest., 74: 647-651, 1984.
49. Heck, M. M., and Earnshaw, W. C. Topoisomerase II: a specific marker for cell proliferation. J. Cell Biol., 103: 2569-2581, 1986.
50. Drewinko, B., Patchen, M., Yang, L-Y., and Barlogie, B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res., 41: 2328-2333, 1981.
51. Baral, E., and Auer, G. In vitro effect of doxorubicin on nonproliferating and proliferating epithelial cells. Int. J. Radiat. Oncol., 19: 963-965, 1990.
52. Minderman, H., Linssen, P. C. M., Wessels, J. M. C., and Haanen, C. Doxorubicin toxicity in relation to the proliferative state of human hematopoietic cells. Exp. Hematol., 19: 110-114, 1991.
53. Remvikos, Y., Beuzeboc, P., Zajdela, A., Voillemot, N., Magdelenat, H., and Pouillart, P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J. Natl. Cancer Inst., 81: 1383-1387, 1989.
54. Hug, V., Johnston, D., Finders, M., and Hortobgyi, G. Use of growth-stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Res., 46: 147-152, 1986.
55. Daidone, M. G., Silvestrini, R., Luisi, A., Mastore, M., Benini, E., Veneroni, S., Brambilla, C., Ferrari, L., Greco, M., Andreola, S., and Veronesi, U. Changes in biological markers after primary chemotherapy for breast cancer. Int. J. Cancer, 4: 301-305, 1995.
56. Mueller, H., Loop, P., Liu, R., Wosikowski, K., Kueng, W., and Eppenberger, U. Differential signal transduction of epidermal growth factor receptors in hormone-dependent and hormone-independent human breast cancer cells. Eur. J. Biochem., 221: 631-637, 1994.
57. Filmus, F., Pollak, M. N., Cailleau, R., and Buick, R. N. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem. Biophys. Res. Commun., 128: 898-905, 1985.
58. Warri, A. M., Laine, A. M., Majasuo, K. E., Alitalo, K. K., and Harkonen, P. L. Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. Int. J. Cancer, 49: 616-623, 1991.